Search

Bioymifi

Upon binding to the death receptor 5 (DR5) on cancer cells, bioymifi triggers apoptosis, possibly through a caspase-dependent pathway. Bioymifi is currently being investigated as an anti-tumor agent.

Metreleptin

in food intake. … [L41315] In February 2014, metreleptin was approved by the FDA for the treatment of complications of leptin deficiency, as an adjunct to diet, in patients with congenital generalized or acquired generalized

Corticotropin

It is an important player in the hypothalamic-pituitary-adrenal axis.

Cefiderocol

[L10893] It is indicated for use in complicated urinary tract infections in patients with limited or no alternative treatments available. … [A189150] A concern noted in the trial was a 0.3% higher rate of all cause mortality, the cause of which has not been determined.

Esketamine

The FDA approved ketamine (Ketalar) in 1970. … [L5593] Esketamine may prove to be a promising treatment for patients diagnosed with major depressive disorder who have not experienced an improvement in symptoms despite treatment with various medications

Bordetella pertussis pertactin antigen (formaldehyde inactivated)

Pindolol

[A231059] Research into pindolol's use in the treatment of hypertension began in the early 1970s.[A231064] Pindolol was granted FDA approval on 3 September 1982.[L32348] … Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension.

Busulfan

According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen. … Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards.

Oxantel

Oxantel is an anthelmintic drug that targets parasitic acetylcholine receptors.[A275093, A275098]

Cevimeline

Cevimeline is a parasympathomimetic agent that act as an agonist at the muscarinic acetylcholine receptors M1 and M3.